PDF(Pubmed)
Abstract：
UNASSIGNED: Role of complement fraction 5a (C5a), interleukin (IL)-9, and apolipoprotein (apo) A-IV as biomarkers of disease severity and antihistamine response in chronic spontaneous urticaria (CSU) remains elusive.
UNASSIGNED: To identify the role of C5a, IL-9, and apo A-IV as potential biomarkers in predicting disease severity and antihistamine response in CSU patients.
UNASSIGNED: This was a prospective observational study of 95 patients and 42 controls. Serum analysis of C5a, IL-9, and apo A-IV was done using enyzme linked immunosorbent assay kits. Also, serum IgE and anti-thyroid peroxidase (TPO) levels were assessed in all patients. All patients were started on oral levocetirizine 5 mg at baseline and dose was titrated upwards to maximum of 20 mg based on response. Patients were categorized into antihistamine responders or nonresponders as per their disease response. Serological markers, serum IgE, and anti-TPO were correlated with baseline disease severity and antihistamine response.
UNASSIGNED: C5a levels were significantly higher in cases as compared to controls (P = 0.004). Significantly higher IL-9 levels were observed in antihistamine responders than nonresponders (P = 0.008). Baseline urticaria severity demonstrated a statistically significant positive and negative correlations with IL-9 (ρ = 0.277, P = 0.007) and apo A-IV (ρ = -0.271, P = 0.008) levels, respectively. Levels of serum IgE (P = 0.031) and anti-TPO (P = 0.039) were significantly higher in antihistamine nonresponders compared to responders.
UNASSIGNED: IL-9 and apo A-IV might be potential novel biomarkers to predict urticaria severity. Higher IL-9 might be a predictor of antihistamine response. Elevated anti-TPO and serum IgE might predict poor antihistamine response.
UNASSIGNED: To identify the role of C5a, IL-9, and apo A-IV as potential biomarkers in predicting disease severity and antihistamine response in CSU patients.
UNASSIGNED: This was a prospective observational study of 95 patients and 42 controls. Serum analysis of C5a, IL-9, and apo A-IV was done using enyzme linked immunosorbent assay kits. Also, serum IgE and anti-thyroid peroxidase (TPO) levels were assessed in all patients. All patients were started on oral levocetirizine 5 mg at baseline and dose was titrated upwards to maximum of 20 mg based on response. Patients were categorized into antihistamine responders or nonresponders as per their disease response. Serological markers, serum IgE, and anti-TPO were correlated with baseline disease severity and antihistamine response.
UNASSIGNED: C5a levels were significantly higher in cases as compared to controls (P = 0.004). Significantly higher IL-9 levels were observed in antihistamine responders than nonresponders (P = 0.008). Baseline urticaria severity demonstrated a statistically significant positive and negative correlations with IL-9 (ρ = 0.277, P = 0.007) and apo A-IV (ρ = -0.271, P = 0.008) levels, respectively. Levels of serum IgE (P = 0.031) and anti-TPO (P = 0.039) were significantly higher in antihistamine nonresponders compared to responders.
UNASSIGNED: IL-9 and apo A-IV might be potential novel biomarkers to predict urticaria severity. Higher IL-9 might be a predictor of antihistamine response. Elevated anti-TPO and serum IgE might predict poor antihistamine response.
摘要：
■补体部分5a（C5a）的作用，白介素（IL）-9和载脂蛋白（apo）A-IV作为慢性自发性荨麻疹（CSU）疾病严重程度和抗组胺反应的生物标志物仍然难以捉摸。
■为了确定C5a的作用，IL-9和apoA-IV作为预测CSU患者疾病严重程度和抗组胺反应的潜在生物标志物。
■这是一项对95名患者和42名对照的前瞻性观察性研究。血清C5a分析，使用酶联免疫吸附测定试剂盒完成IL-9和载脂蛋白A-IV。此外，评估所有患者的血清IgE和抗甲状腺过氧化物酶（TPO）水平。所有患者在基线开始口服左西替利嗪5mg，并根据反应将剂量向上滴定至最大20mg。根据疾病反应，将患者分为抗组胺反应者或非反应者。血清学标记,血清IgE,抗TPO与基线疾病严重程度和抗组胺反应相关。
■C5a水平在病例中显著高于对照组(P=0.004)。抗组胺反应者的IL-9水平明显高于非反应者（P=0.008）。基线荨麻疹严重程度与IL-9（ρ=0.277，P=0.007）和apoA-IV（ρ=-0.271，P=0.008）水平呈显著正相关和负相关，分别。血清IgE（P=0.031）和抗TPO（P=0.039）的水平明显高于抗组胺无反应者。
■IL-9和载脂蛋白A-IV可能是预测荨麻疹严重程度的潜在新型生物标志物。较高的IL-9可能是抗组胺反应的预测因子。抗TPO和血清IgE升高可能预示抗组胺反应不良。
■为了确定C5a的作用，IL-9和apoA-IV作为预测CSU患者疾病严重程度和抗组胺反应的潜在生物标志物。
■这是一项对95名患者和42名对照的前瞻性观察性研究。血清C5a分析，使用酶联免疫吸附测定试剂盒完成IL-9和载脂蛋白A-IV。此外，评估所有患者的血清IgE和抗甲状腺过氧化物酶（TPO）水平。所有患者在基线开始口服左西替利嗪5mg，并根据反应将剂量向上滴定至最大20mg。根据疾病反应，将患者分为抗组胺反应者或非反应者。血清学标记,血清IgE,抗TPO与基线疾病严重程度和抗组胺反应相关。
■C5a水平在病例中显著高于对照组(P=0.004)。抗组胺反应者的IL-9水平明显高于非反应者（P=0.008）。基线荨麻疹严重程度与IL-9（ρ=0.277，P=0.007）和apoA-IV（ρ=-0.271，P=0.008）水平呈显著正相关和负相关，分别。血清IgE（P=0.031）和抗TPO（P=0.039）的水平明显高于抗组胺无反应者。
■IL-9和载脂蛋白A-IV可能是预测荨麻疹严重程度的潜在新型生物标志物。较高的IL-9可能是抗组胺反应的预测因子。抗TPO和血清IgE升高可能预示抗组胺反应不良。
